The London biotech Charm Therapeutics is looking for a new top executive to replace founding CEO Laksh Aithani, Endpoints ...

A CDC advisory panel voted to recommend RSV vaccines for at-risk adults 50 to 59, a sought-after expansion by vaccine makers ...

Trump's drug pricing EO includes wins on pill penalty reform, faster approvals, and PBM rules, but adds scrutiny on pricing ...

Port Therapeutics and other early biotech startups face funding challenges as investors prefer clinical-stage companies, with ...

A rival bid by Ayrmid for bluebird bio hasn't crossed the finish line, the biotech said, after failing to confirm financing ...

Trump signs EO on drug pricing, supports PhRMA reforms for Medicare negotiations timeline, calls for Canadian drug imports, ...

Glycomine raises $115M Series C to advance GLM101, a mannose-1-phosphate therapy for PMM2-CDG rare disease, toward Phase 2b ...

GeneDx will pay up to $33 million in cash upon the deal's expected closing this quarter. GeneDx could spend up to $51 million ...

Trump's pharma tariffs prompt companies to assess vulnerabilities. J&J expects $400M in costs. Immunocore's Kimmtrak, Acadia's Nuplazid & Daybue may face impact. Companies highlight US manufacturing ...

Roche devastated the Angelman syndrome community in 2023, when it ended clinical development of rugonersen, a treatment ...

The Johnson & Johnson CEO subtly but assertively criticized the Trump administration’s plans for pharmaceutical tariffs, ...

Boston and Dublin biotech Mural Oncology is laying off nearly all of its employees and ending clinical development of its ...